SOXC and MiR17-92 gene expression profiling defines two subgroups with different clinical outcome in mantle cell lymphoma
Alejandro Roisman
Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina (ANM), Buenos Aires, Argentina
Search for more papers by this authorFuad Huamán Garaicoa
Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina (ANM), Buenos Aires, Argentina
FUNDALEU, Buenos Aires, Argentina
Search for more papers by this authorFernanda Metrebian
División Patología, Instituto de Investigaciones Hematológicas, ANM, Buenos Aires, Argentina
Search for more papers by this authorMarina Narbaitz
FUNDALEU, Buenos Aires, Argentina
División Patología, Instituto de Investigaciones Hematológicas, ANM, Buenos Aires, Argentina
Search for more papers by this authorDana Kohan
Servicio de Patología, Hospital Italiano, Buenos Aires, Argentina
Search for more papers by this authorHernán García Rivello
Servicio de Patología, Hospital Italiano, Buenos Aires, Argentina
Search for more papers by this authorLuis Hernández
Patología Molecular, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, España
Search for more papers by this authorCorresponding Author
Irma Slavutsky
Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina (ANM), Buenos Aires, Argentina
Correspondence to: Irma Slavutsky, MD, PhD, Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental CONICET-Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, C1425AUM, Buenos Aires, Argentina. E-mail: [email protected]Search for more papers by this authorAlejandro Roisman
Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina (ANM), Buenos Aires, Argentina
Search for more papers by this authorFuad Huamán Garaicoa
Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina (ANM), Buenos Aires, Argentina
FUNDALEU, Buenos Aires, Argentina
Search for more papers by this authorFernanda Metrebian
División Patología, Instituto de Investigaciones Hematológicas, ANM, Buenos Aires, Argentina
Search for more papers by this authorMarina Narbaitz
FUNDALEU, Buenos Aires, Argentina
División Patología, Instituto de Investigaciones Hematológicas, ANM, Buenos Aires, Argentina
Search for more papers by this authorDana Kohan
Servicio de Patología, Hospital Italiano, Buenos Aires, Argentina
Search for more papers by this authorHernán García Rivello
Servicio de Patología, Hospital Italiano, Buenos Aires, Argentina
Search for more papers by this authorLuis Hernández
Patología Molecular, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, España
Search for more papers by this authorCorresponding Author
Irma Slavutsky
Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina (ANM), Buenos Aires, Argentina
Correspondence to: Irma Slavutsky, MD, PhD, Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental CONICET-Academia Nacional de Medicina, J.A. Pacheco de Melo 3081, C1425AUM, Buenos Aires, Argentina. E-mail: [email protected]Search for more papers by this authorSupported by: National Research Council (CONICET), Grant number: PIP 2012-00517; the National Agency of Scientific and Technical Promotion (ANPCyT), Grant number: PICT 2014-1566; European Regional Development Fund (ERDF) (Unión Europea. “Una manera de hacer Europa”), Grant number: PI12/01302; the Alberto J. Roemmers¨ Foundation, the National Ministry of Health through the Health Research Grant Carrillo-Oñativia, Buenos Aires, Argentina, and the Instituto de Salud Carlos III (ISCIII), “Fondo Investigaciones Sanitarias” Centro Esther Koplowitz, Barcelona, Spain.
Abstract
Mantle cell lymphoma (MCL) is a heterogeneous B-cell lymphoid malignancy where most patients follow an aggressive clinical course whereas others are associated with an indolent performance. SOX4, SOX11, and SOX12 belong to SOXC family of transcription factors involved in embryonic neurogenesis and tissue remodeling. Among them, SOX11 has been found aberrantly expressed in most aggressive MCL patients, being considered a reliable biomarker in the pathology. Several studies have revealed that microRNAs (miRs) from the miR-17-92 cluster are among the most deregulated miRNAs in human cancers, still little is known about this cluster in MCL. In this study we screened the transcriptional profiles of 70 MCL patients for SOXC cluster and miR17, miR18a, miR19b and miR92a, from the miR-17-92 cluster. Gene expression analysis showed higher SOX11 and SOX12 levels compared to SOX4 (P ≤ 0.0026). Moreover we found a negative correlation between the expression of SOX11 and SOX4 (P < 0.0001). miR17-92 cluster analysis showed that miR19b and miR92a exhibited higher levels than miR17 and miR18a (P < 0.0001). Unsupervised hierarchical clustering revealed two subgroups with significant differences in relation to aggressive MCL features, such as blastoid morphological variant (P = 0.0412), nodal presentation (P = 0.0492), CD5+ (P = 0.0004) and shorter overall survival (P < 0.0001). Together, our findings show for the first time an association between the differential expression profiles of SOXC and miR17-92 clusters in MCL and also relate them to different clinical subtypes of the disease adding new biological information that may contribute to a better understanding of this pathology. © 2016 Wiley Periodicals, Inc.
Supporting Information
Additional Supporting Information may be found in the online version of this article.
| Filename | Description |
|---|---|
| gcc22355-sup-0001-suppfig1.tif764.9 KB |
Supporting Information Figure 1. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- Aaboe M, Birkenkamp-Demtroder K, Wiuf C, Sørensen FB, Thykjaer T, Sauter G, Jensen KM, Dyrskjøt L, Ørntoft T. 2006. SOX4 expression in bladder carcinoma: Clinical aspects and in vitro functional characterization. Cancer Res 7: 3434–3442.
- Andersen CL, Christensen LL, Thorsen K, Schepeler T, Sørensen FB, Verspaget HW, Simon R, Kruhøffer M, Aaltonen LA, Laurberg S, Ørntoft TF. 2009. Dysregulation of the transcription factors SOX4, CBFB and SMARCC1 correlates with outcome of colorectal cancer. Br J Cancer 3: 511–523.
- Bergsland M, Werme M, Malewicz M, Perlmann T, Muhr J. 2006. The establishment of neuronal properties is controlled by Sox4 and Sox11. Genes Dev 20: 3475–3486.
- Bhattaram P, Penzo-Méndez A, Sock E, Colmenares C, Kaneko KJ, Vassilev A, Depamphilis ML, Wegner M, Lefebvre V. 2010. Organogenesis relies on SoxC transcription factors for the survival of neural and mesenchymal progenitors. Nat Commun 12: 1– 9.
- Caballero D, Campo E, López-Guillermo A, Martín A, Arranz-Sáez R, Giné E, López A, González-Barca E, Canales MÁ, González-Díaz M, Orfao A. 2013. Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. Ann Hematol 9: 1151–1179.
- Campo E, Rule S. 2015. Mantle cell lymphoma: Evolving management strategies. Blood 1: 48–55.
- Castellano L, Giamas G, Jacob J, Coombes RC, Lucchesi W, Thiruchelvam P, Barton G, Jiao LR, Wait R, Waxman J, Hannon GJ, Stebbing J. 2009. The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci USA 106: 15732–15737.
- Chen L, Li C, Zhang R, Gao X, Qu X, Zhao M, Qiao C, Xu J, Li J. 2011. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett 1: 62–70.
- Coller HA, Forman JJ, Legesse-Miller A. 2007. “Myc'ed messages”: myc induces transcription of E2F1 while inhibiting its translation via a microRNApolycistron. PLoS Genet 8: e146.
- deBont JM, Packer RJ, Michiels EM, den Boer ML, Pieters R. 2008. Biological background of pediatric medulloblastoma and ependymoma: A review from a translational research perspective. Neuro Oncol 6: 1040–1060.
- Dictor M, Ek S, Sundberg M, Warenholt J, György C, Sernbo S, Gustavsson E, Abu-Alsoud W, Wadström T, Borrebaeck C. 2009. Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. Haematologica 11: 1563–1568.
- Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, Mongera S, Postma C, Meijerink WJ, Carvalho B, Meijer GA. 2009. MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer 4: 707–714.
- Dy P, Penzo-Méndez A, Wang H, Pedraza CE, Macklin WB, Lefebvre V. 2008. The three SoxC proteins -Sox4, Sox11 and Sox12- exhibit overlapping expression patterns and molecular properties. Nucleic Acids Res 36: 3101–3117.
- Eiriksdottir G, Johannesdottir G, Ingvarsson S, Björnsdottir IB, Jonasson JG, Agnarsson BA, Hallgrimsson J, Gudmundsson J, Egilsson V, Sigurdsson H, Barkardottir RB. 1998. Mapping loss of heterozygosity at chromosome 13q: Loss at 13q12-q13 is associated with breast tumour progression and poor prognosis. Eur J Cancer 13: 2076–2081.
- Ek S, Dictor M, Jerkeman M, Jirström K, Borrebaeck CA. 2008. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 2: 800–805.
- Fabbri M, Croce CM. 2011. Role of microRNAs in lymphoid biology and disease. Curr Opin Hematol 4: 266–272.
- Fernández V, Salamero O, Espinet B, Solé F, Royo C, Navarro A, Camacho F, Beà S, Hartmann E, Amador V, Hernández L, Agostinelli C, Sargent RL, Rozman M, Aymerich M, Colomer D, Villamor N, Swerdlow SH, Pileri SA, Bosch F, Piris MA, Montserrat E, Ott G, Rosenwald A, López-Guillermo A, Jares P, Serrano S, Campo E. 2010. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 4: 1408–1418.
- Ghosh AK, Shanafelt TD, Cimmino A, Taccioli C, Volinia S, Liu CG, Calin GA, Croce CM, Chan DA, Giaccia AJ, Secreto C, Wellik LE, Lee YK, Mukhopadhyay D, Kay NE. 2009. Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood 22: 5568–5574.
- Gustavsson E, Sernbo S, Andersson E, Brennan DJ, Dictor M, Jerkeman M, Borrebaeck CA, Ek S. 2010. SOX11 expression correlates to promoter methylation and regulates tumor growth in hematopoietic malignancies. Mol Cancer 12: 187.
- Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T. 2005. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 21: 9628–9632.
- Hoser M, Potzner MR, Koch JM, Bösl MR, Wegner M, Sock E. 2008. Sox12 deletion in the mouse reveals nonreciprocal redundancy with the related Sox4 and Sox11 transcription factors. Mol Cell Biol 15: 4675–4687.
- Hossain A, Kuo MT, Saunders GF. 2006. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol 21: 8191–8201.
- Huang W, Chen Z, Shang X, Tian D, Wang D, Wu K, Fan D, Xia L. 2015. Sox12, a direct target of FoxQ1, promotes hepatocellular carcinoma metastasis through up-regulating Twist1 and FGFBP1. Hepatology 6: 1920–1933.
- Humphreys KJ, Cobiac L, Le Leu RK, Van der Hoek MB, Michael MZ. 2013. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog 6: 459–474.
- Iqbal J, Shen Y, Liu Y, Fu K, Jaffe ES, Liu C, Liu Z, Lachel CM, Deffenbacher K, Greiner TC, Vose JM, Bhagavathi S, Staudt LM, Rimsza L, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, McKeithan TW, Chan WC. 2012. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood 21: 4939–4948.
- Jafarnejad SM, Ardekani GS, Ghaffari M, Martinka M, Li G. 2013. Sox4-mediated Dicer expression is critical for suppression of melanoma cell invasion. Oncogene 17: 2131–2139.
- Jares P, Colomer D, Campo E. 2007. Genetic and molecular pathogenesis of mantle cell lymphoma: Perspectives for new targeted therapeutics. Nat Rev Cancer 10: 750–756.
- Jay P, Sahly I, Gozé C, Taviaux S, Poulat F, Couly G, Abitbol M, Berta P. 1997. SOX22 is a new member of the SOX gene family, mainly expressed in human nervous tissue. Hum Mol Genet 7: 1069–1077.
- Krutilina R, Sun W, Sethuraman A, Brown M, Seagroves TN, Pfeffer LM, Ignatova T, Fan M. 2014. MicroRNA-18a inhibits hypoxia-inducible factor 1α activity and lung metastasis in basal breast cancers. Breast Cancer Res 4: R78.
- Lee CJ, Appleby VJ, Orme AT, Chan WI, Scotting PJ. 2002. Differential expression of SOX4 and SOX11 in medulloblastoma. J Neurooncol 3: 201–214.
- Lefebvre V, Dumitriu B, Penzo-Méndez A, Han Y, Pallavi B. 2007. Control of cell fate and differentiation by Sry-related high-mobility-group box (Sox) transcription factors. Int J Biochem Cell Biol 12: 2195–2214.
- Li M, Guan X, Sun Y, Mi J, Shu X, Liu F, Li C. 2014. miR-92a family and their target genes in tumorigenesis and metastasis. Exp Cell Res 1: 1–6.
- Lin S, Gregory RI. 2015. MicroRNA biogenesis pathways in cancer. 2015. Nat Rev Cancer 6: 321–333.
- Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB, Williams H, Karanam S, Datta MW, Jaye DL, Moreno CS. 2006. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 8: 4011–4019.
- Matsubara H, Takeuchi T, Nishikawa E, Yanagisawa K, Hayashita Y, Ebi H, Yamada H, Suzuki M, Nagino M, Nimura Y, Osada H, Takahashi T. 2007. Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene 41: 6099–6105.
- Mavrakis KJ, Wolfe AL, Oricchio E, Palomero T, de Keersmaecker K, McJunkin K, Zuber J, James T, Khan AA, Leslie CS, Parker JS, Paddison PJ, Tam W, Ferrando A, Wendel HG. 2010. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol 4: 372–379.
- Medina PP, Castillo SD, Blanco S, Sanz-Garcia M, Largo C, Alvarez S, Yokota J, Gonzalez-Neira A, Benitez J, Clevers HC, Cigudosa JC, Lazo PA, Sanchez-Cespedes M. 2009. The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer. Hum Mol Genet 7: 1343–1352.
- Mendell JT. 2008. miRiad roles for the miR-17-92 cluster in development and disease 2: 217–222.
- Morris KV, Mattick JS. 2014. The rise of regulatory RNA. Nat Rev Genet 423–437.
- Mozos A, Royo C, Hartmann E, De Jong D, Baró C, Valera A, Fu K, Weisenburger DD, Delabie J, Chuang SS, Jaffe ES, Ruiz-Marcellan C, Dave S, Rimsza L, Braziel R, Gascoyne RD, Solé F, López-Guillermo A, Colomer D, Staudt LM, Rosenwald A, Ott G, Jares P, Campo E. 2009. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 11: 1555–1562.
- Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, de Stanchina E, D'Andrea A, Sander C, Ventura A. 2009. Genetic dissection of the miR-17∼92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 23: 2806–2811.
- Musilova K, Mraz M. 2015. MicroRNAs in B-cell lymphomas: How a complex biology gets more complex. Leukemia 5: 1004–1017.
- Navarro A, Beà S, Fernández V, Prieto M, Salaverria I, Jares P, Hartmann E, Mozos A, López-Guillermo A, Villamor N, Colomer D, Puig X, Ott G, Solé F, Serrano S, Rosenwald A, Campo E, Hernández L. 2009. MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in mantle cell lymphomas. Cancer Res 17: 7071–7078.
- Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A, Bikos V, Darzentas N, Papadaki T, Salaverria I, Pinyol M, Puig X, Palomero J, Vegliante MC, Amador V, Martinez-Trillos A, Stefancikova L, Wiestner A, Wilson W, Pott C, Calasanz MJ, Trim N, Erber W, Sander B, Ott G, Rosenwald A, Colomer D, Giné E, Siebert R, Lopez-Guillermo A, Stamatopoulos K, Beà S, Campo E. 2012. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 20: 5307–5316.
- Navarro A, Clot G, Prieto M, Royo C, Vegliante MC, Amador V, Hartmann E, Salaverria I, Beà S, Martín-Subero JI, Rosenwald A, Ott G, Wiestner A, Wilson WH, Campo E, Hernández L. 2013. microRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics. Clin Cancer Res 12: 3121–3129.
- Niu H, Wang K, Zhang A, Yang S, Song Z, Wang W, Qian C, Li X, Zhu Y, Wang Y. 2012. miR-92a is a critical regulator of the apoptosis pathway in glioblastoma with inverse expression of BCL2L11. Oncol Rep 5: 1771–1777.
- Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, Li QJ, Lowe SW, Hannon GJ, He L. 2009. miR-19 is a key oncogenic component of mir-17-92. Genes Dev 23: 2839–2849.
- Ondrejka SL, Lai R, Smith SD, Hsi ED. 2011. Indolent mantle cell leukemia: A clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 8: 1121–1127.
- Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E, Catovsky D, Thomas PW, Avet-Loiseau H, Oscier D. 2003. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 12: 4975–4981.
- Palomero J, Vegliante MC, Rodríguez ML, Eguileor A, Castellano G, Planas-Rigol E, Jares P, Ribera-Cortada I, Cid MC, Campo E, Amador V. 2014. SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood 14: 2235–2247.
- Penzo-Méndez AI. 2010. Critical roles for SoxC transcription factors in development and cancer. Int J Biochem Cell Biol 3: 425–428.
- Pérez-Galán P, Dreyling M, Wiestner A. 2011. Mantle cell lymphoma: Biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 1: 26–38.
- Rao E, Jiang C, Ji M, Huang X, Iqbal J, Lenz G, Wright G, Staudt LM, Zhao Y, McKeithan TW, Chan WC, Fu K. 2012. The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia 5: 1064–1072.
- Royo C, Salaverria I, Hartmann EM, Rosenwald A, Campo E, Beà S. 2011. The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol 5: 322–334.
- Rubio-Moscardo F, Climent J, Siebert R, Piris MA, Martín-Subero JI, Nieländer I, Garcia-Conde J, Dyer MJ, Terol MJ, Pinkel D, Martinez-Climent JA. 2005. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 11: 4445–4454.
- Schilham MW, Oosterwegel MA, Moerer Pl. 1996. Defects in cardiac outflow tract formation and pro-B-lymphocyte expansion in mice lacking Sox-4. Nature 380: 711–714.
- Swerdlow SH, Campo E, Seto M, Muller-Hermelink HK. 2008. Mantle cell lymphoma. In: SH Swerdlow, E Campo, NL Harris, ES Jaffe, SA Pileri, H Stein, J Thiele, JW Vardiman, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC, pp. 229–232.
- Tagawa H, Karube K, Tsuzuki S, Ohshima K, Seto M. 2007. Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development. Cancer Sci 9: 1482–1490.
- Tsuchida A, Ohno S, Wu W, Borjigin N, Fujita K, Aoki T, Ueda S, Takanashi M, Kuroda M. 2011. miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer Sci 12: 2264–2271.
- Vegliante MC, Palomero J, Pérez-Galán P, Roué G, Castellano G, Navarro A, Clot G, Moros A, Suárez-Cisneros H, Beà S, Hernández L, Enjuanes A, Jares P, Villamor N, Colomer D, Martín-Subero JI, Campo E, Amador V. 2013. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood 12: 2175–2185.
- Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. 2006. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 7: 2257–2261.
- Wasik AM, Lord M, Wang X, Zong F, Andersson P, Kimby E, Christensson B, Karimi M, Sander B. 2013. SOXC transcription factors in mantle cell lymphoma: the role of promoter methylation in SOX11 expression. Sci Rep 3: 1400.
- Yu Z, Wang C, Wang M, Li Z, Casimiro MC, Liu M, Wu K, Whittle J, Ju X, Hyslop T, McCue P, Pestell RG. 2008. A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol 182: 509–517.
- Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y, McCue PA, Quong AA, Lisanti MP, Pestell RG. 2010. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci USA 107: 8231–8236.
